← Back to Search

Other

TAK-279 for Psoriasis

Phase 3
Recruiting
Research Sponsored by Takeda
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from start of the drug administration up to week 56 (part a) and week 160 (part b)
Awards & highlights

Summary

This trial aims to study the side effects and tolerance of TAK-279 in people with moderate-to-severe plaque psoriasis. Participants will be given TAK-279 and will continue treatment based on

Who is the study for?
This trial is for adults over 18 with chronic plaque psoriasis for at least 6 months, covering more than 10% of their body. They must be stable, without significant changes in their condition recently and be candidates for phototherapy or systemic therapy. Participants need to understand the study procedures and agree to follow them.
What is being tested?
The trial tests TAK-279's safety and effectiveness in those with moderate-to-severe plaque psoriasis. It involves up to 217 weeks of treatment including a screening period, an initial treatment phase (Part A), an optional extended phase (Part B), and a follow-up.
What are the potential side effects?
While specific side effects are not listed here, participants will monitor how well they tolerate TAK-279 throughout the study duration, focusing on any adverse reactions that may arise from its use.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from start of the drug administration up to week 56 (part a) and week 160 (part b)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from start of the drug administration up to week 56 (part a) and week 160 (part b) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Part A and Part B: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE)
Secondary study objectives
Part A and B: Number of Participants Achieving 75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI-75) Score
Part A and B: Number of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a >=2-point Decrease from Baseline

Trial Design

1Treatment groups
Experimental Treatment
Group I: Part A (De Novo Cohort) + Part B (Open Label Extension): TAK-279Experimental Treatment1 Intervention
Part A: Participants will receive TAK-279, oral tablet once daily (QD) for up to 52 weeks. Part B: Participants who completed the treatment period of parent studies (TAK-279-3001 \[NCT06088043\] or TAK-279-3002 \[NCT06108544\]) or who completed Part A will receive TAK-279, oral tablet QD for up to 156 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TAK-279
2023
Completed Phase 1
~390

Find a Location

Who is running the clinical trial?

TakedaLead Sponsor
1,231 Previous Clinical Trials
4,146,446 Total Patients Enrolled
Study DirectorStudy DirectorTakeda
1,259 Previous Clinical Trials
501,912 Total Patients Enrolled
~867 spots leftby May 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top